News Center

Peijia Medical Partners with inQB8 for US Incubator and Transcatheter Tricuspid Replacement (TTVR) Product

Peijia Medical and CR PHARMA COMM Sign Memorandum of Strategic Cooperation

Peijia Medical’s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

Patient Enrollment Completed for Clinical Trial of Peijia Medical’s Shenyi® Stent Retriever

Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology

Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product

Peijia Medical Successfully Listed on the Main Board of the Stock Exchange of Hong Kong

Peijia Medical Announces Global Offering Results Offer Price is HK$15.36 per Offer Share, Commence Trading on the Main Board of the Hong Kong Stock Exchange On May 15, 2020

Peijia Medical Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange